<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39326930</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>09</Month><Day>26</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1477-0903</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><PubDate><Year>2024</Year><Season>Jan-Dec</Season></PubDate></JournalIssue><Title>Human &amp; experimental toxicology</Title><ISOAbbreviation>Hum Exp Toxicol</ISOAbbreviation></Journal><ArticleTitle>Subchronic oral toxicity assessment of <i>Bacillus velezensis</i> strain BV379 in sprague-dawley rats.</ArticleTitle><Pagination><StartPage>9603271241278977</StartPage><MedlinePgn>9603271241278977</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1177/09603271241278977</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">The spore-forming bacterial species <i>Bacillus velezensis</i> is commonly utilized in feed for livestock and aquaculture. In recent years, there has been increased interest in introducing <i>B</i>. <i>velezensis</i> into human supplements and food. Before it can be safely administered in humans, the safety of each <i>B</i>. <i>velezensis</i> strain needs to be established. The objective of this study was to evaluate the in vivo safety of <i>Bacillus velezensis</i> strain BV379 by high-dose oral administration to rats in a 28-day subchronic toxicity study.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">In this study, 80 animals were assigned to four groups: vehicle control, 1 × 10<sup>10</sup>, 4 × 10<sup>10</sup>, or 10 × 10<sup>10</sup> CFU/kg bw/day by gavage. The following toxicological assessments were performed: ophthalmological examinations; observations for viability, signs of gross toxicity, and behavioral changes; in-life parameters, including body weight and food consumption; urinalysis, hematology, clinical chemistry, and coagulation assessments; macroscopic and microscopic tissue assessments; and bacterial enumeration in selected tissues.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Under the conditions of this study, no adverse clinical endpoints were attributed to the administration of <i>Bacillus velezensis</i> strain BV379, which was well-tolerated up to the highest dose of 10 × 10<sup>10</sup> CFU/kg bw/day.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">These results support the in vivo pre-clinical safety of <i>Bacillus velezensis</i> strain BV379 for use in food and supplements.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bauter</LastName><ForeName>Mark R</ForeName><Initials>MR</Initials><Identifier Source="ORCID">0009-0000-5279-2036</Identifier><AffiliationInfo><Affiliation>Product Safety Labs, Dayton, NJ, USA.</Affiliation><Identifier Source="RINGGOLD">465908</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brutscher</LastName><ForeName>Laura M</ForeName><Initials>LM</Initials><AffiliationInfo><Affiliation>BIO-CAT Microbials LLC, Shakopee, MN, USA.</Affiliation><Identifier Source="RINGGOLD">53651</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dolan</LastName><ForeName>Laurie C</ForeName><Initials>LC</Initials><AffiliationInfo><Affiliation>GRAS Associates, LLC, North Bethesda, MD, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spears</LastName><ForeName>Jessica L</ForeName><Initials>JL</Initials><AffiliationInfo><Affiliation>BIO-CAT Microbials LLC, Shakopee, MN, USA.</Affiliation><Identifier Source="RINGGOLD">53651</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Hum Exp Toxicol</MedlineTA><NlmUniqueID>9004560</NlmUniqueID><ISSNLinking>0960-3271</ISSNLinking></MedlineJournalInfo><SupplMeshList><SupplMeshName Type="Organism" UI="C000649781">Bacillus velezensis</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D001407" MajorTopicYN="Y">Bacillus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017207" MajorTopicYN="Y">Rats, Sprague-Dawley</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000284" MajorTopicYN="N">Administration, Oral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D059550" MajorTopicYN="Y">Toxicity Tests, Subchronic</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019936" MajorTopicYN="N">Probiotics</DescriptorName><QualifierName UI="Q000633" MajorTopicYN="N">toxicity</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051381" MajorTopicYN="N">Rats</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">BV379</Keyword><Keyword MajorTopicYN="N">Bacillus velezensis</Keyword><Keyword MajorTopicYN="N">safety</Keyword><Keyword MajorTopicYN="N">toxicity</Keyword></KeywordList><CoiStatement>Declaration of conflicting interestsThe author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: M.R.B. is an employee of Product Safety Labs, which received compensation for conducting the rat toxicity study. L.M.B and J.L.S. are employees of BIO-CAT Microbials, LLC, which provided funding and manufactured the <i>Bacillus velezensis</i> BV379 spores for this study. BIO-CAT Microbials, LLC is the assignee of a patent application describing compositions and methods of use related to the microbial strain described herein (Patent Application No. 63/512,678). The funders had input into the final study design and interpretation of the data. The funders were also involved in the writing and editing of the manuscript. L.C.D is an employee of GRAS Associates, LLC, a consulting firm that received compensation from BIO-CAT Microbials, LLC for assisting L.M.B and J.L.S. The authors declare no other conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>26</Day><Hour>20</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39326930</ArticleId><ArticleId IdType="doi">10.1177/09603271241278977</ArticleId></ArticleIdList></PubmedData></PubmedArticle>